ASH 2012 CLL Paper Slideshow Summary by Susan ... - CLL Support

CLL Support

22,512 members38,665 posts

ASH 2012 CLL Paper Slideshow Summary by Susan O'Brien and Kanti Rai

AussieNeil profile image
AussieNeilAdministrator
0 Replies

A slideshow summary of CLL related papers, presented at last year's American Society of Hematology (ASH) Annual Meeting is now available from Clinical Care Options (free registration). It provides a good comparison of how various new drug and new drug combinations work with different classes of CLL patients.

clinicaloptions.com/Oncolog...

Key to Common Abbreviations

CR = Complete Response

DOR = Duration of Response

MRD negative = Minimal Residual Disease negative (i.e can't detect CLL)

ORR = Objective Overall Response (sum of PRs and CRs)

OS = Overall Survial

PD = Progressive Disease

PFS = Progression-Free Survival

PR = Partial Remission

SD = Stable Disease

TTF = Time to Treatment Failure

The purpose of many of these are discussed in the paper: Endpoints for Assessing Drug Activity in Clinical Trials

theoncologist.alphamedpress...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Dr. O'Brien on how she treats CLL frontline and Dr. Pagel on new ways to block BTK

frantic mode heading to ASH. We had our poster accepted about research on our own free Expert...

ASH 2012 Interview: Dr Jeff Sharman \"Why New CLL Treatments Supersede FCR\"

replace FCR....

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

ic-lymphocytic-leukemia-cll/ In my #7 of the top 10 CLL abstracts from ASH, I review the...

ASH 2019 CLL highlights and 'hot' topics - Drs Nicole Lamanna & Florence Cymbalista

Lamanna - ASH 2019 - Maturing CLL clinical trial data Dr. Nicole Lamanna, Associate Clinical...

ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL

interview here. http://cllsociety.org/2016/10/asco-2016-acalabrutinib-frontline-cll NEW Patient &...